Fig. 5

Comparison of immune cell compositions with respect to their prognostic predictability. From each of the NAT- and tumor-driven transcriptomes, the proportions of 29 deconvoluted immune cell types were estimated using xCell. Logistic regression analysis was then applied NATs and tumors to determine whether immune cell composition can differentiate patient recurrence. Eight out of the 29 cell types that were significant at P < 0.05 in either NATs or tumors are shown. A The beta coefficient and 95% CI and B the P-value of each cell type are depicted. C Z-score normalized cell proportions per cell type are depicted, and the difference of cell proportions between NAT and tumor samples was tested by the paired-sample t-test. **P < 0.01, ***P < 0.001, ****P < 0.0001. pDC, plasmacytoid dendritic cells; aDC, activated dendritic cells; Th2 cells, T helper 2 cells